Related application of IRAK3 in lung adenocarcinoma prognosis prediction and immunotherapy resistance prediction

By detecting IRAK3 expression levels and machine learning models, predicting the prognosis and immunotherapy resistance of lung adenocarcinoma patients, the problems of insufficient accuracy in predicting lung adenocarcinoma prognosis and unclear mechanism of immunotherapy resistance in the prior art have been solved, and better The therapeutic effect and survival time are prolonged.

CN118918945APending Publication Date: 2024-11-08CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410960508.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing methods for predicting lung adenocarcinoma prognosis, such as the TNM staging system, are insufficiently accurate due to tumor heterogeneity, and the mechanism of immunotherapy resistance is unknown, resulting in poor treatment effect.

Method used

By detecting IRAK3 expression levels, using machine learning models to predict the prognosis and immunotherapy resistance of lung adenocarcinoma patients, provide targeted drug treatment effect prediction, and combine IRAK3's independent prognostic factors and immunotherapy indicators to select appropriate treatment methods to improve treatment effect .

Benefits of technology

The reduced expression level of IRAK3 is significantly related to adverse prognosis. As an independent prognostic factor and immunotherapy indicator, it can help select appropriate treatment methods, improve treatment effect and prolong patient survival time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118918945A_ABST
    Figure CN118918945A_ABST
Patent Text Reader

Abstract

The invention discloses related application of IRAK3 in lung adenocarcinoma prognosis prediction and immunotherapy resistance prediction, and relates to the field of biological medicine. According to the application, the reduction of the expression level of the IRAK3 in the lung adenocarcinoma is obviously related to adverse prognosis, and the IRAK3 can be used as an independent prognosis predictor and an immunotherapy index of LUAD, so that a lung adenocarcinoma patient can select a proper treatment method in time, the treatment effect is improved, and the survival time of the patient is prolonged.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular, to the application of IRAK3 in lung adenocarcinoma prognosis prediction and immunotherapy resistance prediction. Background Art

[0002] Lung cancer, as the main contributor to approximately 18.0% of all cancer deaths, is the leading cause of cancer-related deaths worldwide and continues to pose a major challenge to global health. Lung adenocarcinoma (LUAD) is the main histological subtype, accounting for more than 40% of all diagnosed lung cancer cases. Currently, the main and key method for predicting prognosis in LUAD patients is accurate staging using the TNM (tumor-node-metastasis) staging system. However, tumor heterogeneity weakens the predictive accuracy of TNM staging, suggesting that new molecular prognostic markers should be identified to determine risk stratification and prognosis.

[0003] In view of this, the present invention is proposed. Summary of the invention

[0004] The purpose of the present invention is to provide relevant applications of IRAK3 in lung adenocarcinoma prognosis prediction and immunotherapy resistance prediction.

[0005] The present invention is achieved in that:

[0006] In a first aspect, an embodiment of the present invention provides the use of a reagent for detecting the expression level of IRAK3 in preparing a product for predicting the prognosis of a patient with lung adenocarcinoma.

[0007] In a second aspect, an embodiment of the present invention provides the use of a reagent for detecting the expression level of IRAK3 in the preparation of a product for predicting resistance to immunotherapy and / or predicting the therapeutic effect of a targeted drug.

[0008] In a third aspect, an embodiment of the present invention provides a method for training a prediction model, which is applied to any one or more of the prognosis prediction, immunotherapy resistance prediction and targeted drug treatment effect prediction of patients with lung adenocarcinoma, and comprises: obtaining the detection results of the IRAK3 expression level of the training sample and its corresponding annotation results; inputting the obtained detection results and annotation results into a pre-constructed machine learning model to obtain the prediction results of the sample; and updating the parameters of the machine learning model according to the annotation results and the prediction results.

[0009] In a fourth aspect, an embodiment of the present invention provides a prediction device, which is applied to any one or more of the prognosis prediction, immunotherapy resistance prediction and targeted drug treatment effect prediction of patients with lung adenocarcinoma, and comprises: an acquisition module for obtaining the detection result of the expression level of IRAK3 of the sample to be tested; a prediction module for inputting the obtained detection result into the prediction model trained by the training method described in the aforementioned embodiment to obtain the prediction result of the sample.

[0010] In a fifth aspect, an embodiment of the present invention provides an electronic device comprising a processor and a memory, wherein the memory is used to store a program, and when the program is executed by the processor, the processor enables the processor to achieve any one or more of prognosis prediction of lung adenocarcinoma patients, prediction of immunotherapy resistance, and prediction of therapeutic effect of targeted drugs.

[0011] The step of predicting the prognosis of lung adenocarcinoma patients includes: obtaining the test result of the IRAK3 expression level of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method described in the above embodiment to obtain the prediction result of the prognosis of the sample.

[0012] The step of predicting immunotherapy resistance includes: obtaining the test result of the IRAK3 expression level of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method described in the above embodiment to obtain the prediction result of the immunotherapy resistance of the sample.

[0013] The step of predicting the therapeutic effect of the targeted drug includes: obtaining the test result of the IRAK3 expression level of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method described in the above embodiment to obtain the prediction result of the therapeutic effect of the targeted drug of the sample.

[0014] In a sixth aspect, an embodiment of the present invention provides a computer-readable medium having a computer program stored thereon, which, when executed by a processor, implements any one or more of the prognosis prediction of lung adenocarcinoma patients described in the aforementioned embodiments, the prediction of immunotherapy resistance in the aforementioned embodiments, and the prediction of the therapeutic effect of targeted drugs in the aforementioned embodiments.

[0015] The present invention has the following beneficial effects:

[0016] The present application found that the decreased expression level of IRAK3 in lung adenocarcinoma was significantly correlated with an unfavorable prognosis. IRAK3 can be used as an independent prognostic predictor and immunotherapy indicator for LUAD, which is beneficial for lung adenocarcinoma patients to timely select appropriate treatment methods, improve treatment effects, and prolong patient survival time. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0018] Figure 1 Figure 3 is the expression and methylation level of IRAK3 in different types of human cancers; (A) The data of various cancer datasets in the Oncomine database show that the expression of IRAK3 in cancer tissues is higher or lower than that in normal tissues; (B) The expression level of IRAK3 in different tumors obtained from the Cancer Genome Atlas (TCGA) data from the TIMER database (*P < 0.05, **P < 0.01, ***P < 0.001); (C) The mRNA expression level of IRAK3 gene in lung adenocarcinoma (LUAD) tissues and normal tissues in the TCGA-LUAD cohort data (N = 59; T = 522); (D) According to the TCGA data, the methylation status of IRAK3 in different types of cancer and corresponding normal tissues (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001); (E) The expression level of IRAK3 in the TCGA-LUAD cohort is higher than that in the normal tissues (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Pearson correlation coefficient between mRNA expression and methylation level of each CpG site of IRAK3 gene; (F) Scatter plot showing the methylation status of two CpG sites (cg20395892, cg26279550) in the promoter region of IRAK3, which is associated with decreased IRAK3 expression in 476 LUAD tissue samples; TPM, transcripts per million; 5'UTR, 5' untranslated region; 3'UTR, 3' untranslated region;

[0019] Figure 2IRAK3 is often downregulated in LUAD tissues, and lack of IRAK3 indicates a poor prognosis; (A) Immunohistochemistry (IHC) staining showed that IRAK3 was often downregulated in LUAD relative to adjacent non-tumor tissues (****P<0.0001); (B) Representative images of IHC staining of IRAK3 in LUAD tumor tissues and non-tumor tissues; (C) Survival analysis results of IRAK3 expression levels measured by IHC in 222 LUAD patients from the National Cancer Center, and survival rates were compared by Kap Kaplan-Meier survival curves are presented; (D) OS and PFS survival curves of lung cancer patients (n=2166, n=1252) in the Kaplan-Meier plot database; (E) OS and PFS survival curves of LUAD patients (n=1161, n=906) and LUSC patients (n=780, n=220) in the Kaplan-Meier plot database; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; LUSC, lung squamous cell carcinoma;

[0020] Figure 3 The expression of IRAK3 can predict the clinical prognosis of LUAD patients with lymph node metastasis; Kaplan-Meier survival curve (OS) compared the prognostic differences between the high- and low-expression groups of IRAK3 in N0 (A) and N1+2 (B) stage LUAD patients from the National Cancer Center (NCC) cohort; Kaplan-Meier survival curve also compared the overall survival differences between the high- and low-expression groups of IRAK3 in the N0 (C) and N1 (D) stage LUAD cohort in the Kaplan-Meier mapping database; OS, overall survival; HR, hazard ratio; CI, confidence interval;

[0021] Figure 4 Genes co-expressed with IRAK3 in LUAD and signaling pathways affected by the IRAK3 gene; (A) Each gene significantly associated with IRAK3 was distinguished from the TCGA-LUAD cohort in the linkage multi-omics database by Pearson test; (B, C) Heat maps show the top 50 genes positively correlated with IRAK3 and the top 50 genes negatively correlated with IRAK 3 in LUAD, respectively; (D) Survival heat map of the top 50 genes positively and negatively correlated with IRAK3 in LUAD; (E) KEGG pathway gene set enrichment analysis (GSEA) results of IRAK3 co-expressed genes in the LUAD cohort; (F) GO term annotation enrichment analysis of IRAK3 co-expressed genes in the LUAD cohort;

[0022] Figure 5This is a study on the correlation between IRAK3 expression and immune infiltration level in LUAD patients; (A) The CIBERSORT algorithm was used to analyze the different infiltration levels of 20 immune cells in tumors of the IRAK3 high expression group and low expression group in the LUAD cohort (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001); (B) The correlation between immune cell infiltration and IRAK3 expression level; (C, D) IRAK3 expression was significantly positively correlated with the infiltration level of macrophages and CD4+ memory resting T cells (****P<0.0001); (E) The correlation between IRAK3 expression and immune score, matrix score and ESTIMATE score in LUAD patients;

[0023] Figure 6 Results of correlation analysis between IRAK3 expression and immune infiltration level in LUAD; (A) Correlation between immune cell infiltration and IRAK3 expression from TIMER database; (B) Scatter plot of correlation between immune cell infiltration and IRAK3 expression from TISIDB database; (C) Lollipop plot of correlation analysis results obtained by EPIC, QUANTISEQ, XCELL and MCPCOUNTER algorithms;

[0024] Figure 7 The expression of IRAK3 at the single-cell level; (A) UMAP plots indicate cell clusters in different LUAD datasets and the expression levels of IRAK3 in different cell types; (B) IRAK3 expression profiles in different cell types in LUAD; (C) Heat map of IRAK3 expression levels in different cell types in all NSCLC cohorts in the TISCH database; (D) Correlation between IRAK3 expression and myeloid cell lineage-specific genes in the TCGA-LUAD cohort;

[0025] Figure 8Figure 3 Correlation between IRAK3 expression and immunotherapy response; (A) IRAK3 expression was higher in ICB-resistant LUAD patients (n=220) than in ICB-responsive LUAD patients (n=285) (*P<0.05); (B) TMB of LUAD patients with high and low IRAK3 expression (***P<0.001); (C) Wilcoxon test for TIDE score, T cell dysfunction score, T cell rejection score and MSI between high and low IRAK3 expression subgroups (***P<0.001, ****P<0.0001); (D) Effect of IRAK3 on CTL dysfunction in TCGA-LUAD cohort; (E) Violin plot showing differential expression of immune checkpoint markers in different IRAK3 subgroups (**P<0.01, ****P<0.0001); (F) Correlation between IRAK3 and known immune checkpoint markers in LUAD; (G) Hallmark gene set of LUAD samples The results of enrichment analysis of sets) were summarized in Figure 2; TMB, tumor mutation burden; TIDE, tumor immune dysfunction and rejection; MSI, microsatellite instability; CTL, cytotoxic T lymphocyte; NES, normalized enrichment score;

[0026] Fig. 9 Figure 2 Gene set enrichment analysis (GSEA) and co-expression analysis of LUAD samples with high and low IRAK3 expression; (A) GSEA results of interferon-γ response pathway in LUAD cohort; (B) GSEA results of inflammatory response pathway in LUAD cohort; (C) GSEA results of IL6 / JAK / STAT3 signaling pathway in LUAD cohort; (D) Correlation between IRAK3 and key components of interferon-γ response pathway, inflammatory response pathway and IL-6 / JAK / STAT3 signaling pathway (***P<0.001); NES, normalized enrichment score; FDR, false discovery rate;

[0027] Fig.10 To evaluate the chemotherapy sensitivity associated with IRAK3 expression levels; (A) Correlation between IRAK3 expression and the response to 6 commonly used chemotherapeutic drugs and molecular targeted drugs; (B) Sensitivity of patients in the high and low IRAK3 groups to the same 6 drugs (***P<0.001); IC50, half maximal inhibitory concentration;

[0028] Fig.11In the validation cohort of 84 LUAD patients, IRAK3 expression was significantly expressed as a marker for predicting the effect of immunotherapy; (A) RT-qPCR was used to detect IRAK3 expression in the immune response group and the non-response group in 84 tumor samples; (B) In the validation cohort, the receiver operating characteristic (ROC) curve of IRAK3 expression for predicting the effect of immunotherapy was obtained; (C) The sensitivity and specificity results of IRAK3 expression as a predictor of immunotherapy effect when different cutoff values ​​were used. 0.4171 was selected as the cutoff value, with a specificity of 88.10% and a sensitivity of 85.71%. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0030] This application found that the expression level of IRAK3 in lung adenocarcinoma is associated with an unfavorable prognosis of lung adenocarcinoma, especially individuals with lymphatic metastasis. Gene set enrichment analysis (GSEA) and tumor infiltration analysis demonstrated that IRAK3 promoted immune infiltration. Macrophages / monocytes, CD4+T cells, CD8+T cells, and neutrophils were significantly associated with IRAK3 expression. By the TIDE algorithm, IRAK3 was confirmed to be associated with a poor immune checkpoint blockade response. IRAK3 was positively correlated with T cell dysfunction scores and immune checkpoint markers. In contrast, it was negatively correlated with microsatellite instability (MSI) and tumor mutation burden (TMB). Increased IRAK3 expression levels exacerbated cytotoxic T lymphocyte (CTL) dysfunction through multiple inflammatory-related pathways including IL-6 / JAK / STAT3 signaling, inflammatory response, and interferon-γ response pathways, and IRAK3 expression levels could predict patients' resistance to immunotherapy. In addition, high expression of IRAK3 is associated with better response to chemotherapy and molecular targeted drugs. Detecting the expression level of IRAK3 can predict the sensitivity to chemotherapy and molecular targeted drugs.

[0031] On the one hand, an embodiment of the present invention provides the use of a reagent for detecting the expression level of IRAK3 in preparing a product for predicting the prognosis of a patient with lung adenocarcinoma.

[0032] In some embodiments, the predicting the prognosis of a lung adenocarcinoma patient comprises predicting the survival period of the lung adenocarcinoma patient and / or predicting the 1-year, 3-year, and 5-year survival rate of the patient.

[0033] In some embodiments, the lung adenocarcinoma patients include lung adenocarcinoma patients with lymph node metastasis.

[0034] In some embodiments, the IRAK3 expression level comprises at least one of an IRAK3 protein expression level and an IRAK3 mRNA expression level.

[0035] In some embodiments, the type of the product can be selected from any one of a reagent, a kit, and a chip.

[0036] The present application has no special restrictions on the type of reagents for detecting the expression level of IRAK3. Existing public or commercially available products can be selected for the detection, which is not the main invention of the present application. In some embodiments, the reagents for detecting the expression level of IRAK3 protein may include: reagents required for any method based on flow cytometry, CITE-seq technology, immunohistochemistry, immunoblotting, ELISA, protein chip and two-dimensional electrophoresis.

[0037] On the other hand, an embodiment of the present invention provides the use of a reagent for detecting the expression level of IRAK3 in the preparation of a product for predicting resistance to immunotherapy and / or predicting the therapeutic effect of a targeted drug.

[0038] In some embodiments, the immunotherapy comprises immune checkpoint inhibitor therapy (ICB).

[0039] In some embodiments, the targeted drug includes at least one of dapafenib, crizotinib, epirubicin, oxaliplatin, AZD8055 and Taselisib.

[0040] On the other hand, an embodiment of the present invention further provides a method for training a prediction model, wherein the prediction model is applied to any one or more of the prognosis prediction, immunotherapy resistance prediction, and targeted drug treatment effect prediction of patients with lung adenocarcinoma, and comprises:

[0041] Obtain the detection results of the IRAK3 expression level of the training samples and their corresponding annotation results;

[0042] Input the obtained detection results and annotation results into the pre-built machine learning model to obtain the prediction results of the samples;

[0043] According to the labeling results and prediction results, the parameters of the machine learning model are updated.

[0044] In some embodiments, the annotation result may be a label representing any one or more of a sample prognosis result, an immunotherapy resistance result, and a therapeutic effect of a targeted drug. The label may be a character or a string. The content of the prediction result corresponds to the content of the annotation result.

[0045] It is understandable that the categories and number of training samples can be routinely selected by those skilled in the art, and the number of total training samples and training samples of various categories (e.g., healthy people and patients) can be ≥ any value or range between any two of 10, 50, 100, 200, 300, 400 and 500. The training samples can include a positive group (e.g., good prognosis) and a negative group (e.g., poor prognosis).

[0046] In some embodiments, the present invention has no particular restrictions on the type of machine learning model, and can be selected from algorithm models conventionally used in the art for prognosis prediction, immunotherapy resistance prediction, and drug treatment effect prediction. Optionally, the machine learning model can be selected from any one of: logistic regression, SVM, Random Forest, Gradient Boosting Classifier (GBC), KNN, decision tree, and naive Bayes.

[0047] On the other hand, an embodiment of the present invention further provides a prediction device, which is applied to any one or more of the prognosis prediction, immunotherapy resistance prediction and targeted drug treatment effect prediction of patients with lung adenocarcinoma, and includes:

[0048] An acquisition module is used to obtain the detection result of the expression level of IRAK3 of the sample to be tested;

[0049] The prediction module is used to input the obtained detection results into the prediction model trained by the training method described in any of the above embodiments to obtain the prediction results of the samples.

[0050] The modules described in the embodiments of the present invention may be stored in a memory in the form of software or firmware or solidified in the operating system (OS) of the electronic device provided by the present application, and may be executed by a processor in the electronic device. At the same time, the data and program codes required to execute the above modules may be stored in the memory.

[0051] On the other hand, an embodiment of the present invention further provides an electronic device, comprising a processor and a memory, wherein the memory is used to store a program, and when the program is executed by the processor, the processor implements any one or more of prognosis prediction, immunotherapy resistance prediction, and treatment effect prediction of targeted drugs for patients with lung adenocarcinoma;

[0052] The step of predicting the prognosis of patients with lung adenocarcinoma comprises: obtaining the test result of the expression level of IRAK3 of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method described in any of the above embodiments to obtain the prediction result of the prognosis of the sample;

[0053] The step of predicting immunotherapy resistance comprises: obtaining the test result of the expression level of IRAK3 of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method described in any of the above embodiments to obtain the prediction result of the immunotherapy resistance of the sample;

[0054] The step of predicting the therapeutic effect of the targeted drug includes: obtaining the test result of the IRAK3 expression level of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method described in any of the above embodiments to obtain the prediction result of the therapeutic effect of the targeted drug of the sample.

[0055] An electronic device may include a memory, a processor, a bus, and a communication interface, wherein the memory, the processor, and the communication interface are electrically connected to each other directly or indirectly to achieve data transmission or interaction. For example, these components may be electrically connected to each other via one or more buses or signal lines.

[0056] The memory can be, but is not limited to, random access memory (RAM), read only memory (ROM), programmable read-only memory (PROM), erasable programmable read-only memory (EPROM), electrically erasable read-only memory (EEPROM), etc.

[0057] The processor can be an integrated circuit chip with signal processing capabilities. The processor 120 can be a general-purpose processor, including a central processing unit (CPU), a network processor (NP), etc.; it can also be a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic devices, discrete gate or transistor logic devices, discrete hardware components.

[0058] The electronic device can be a server, a cloud platform, a mobile phone, a tablet computer, a laptop computer, an ultra-mobile personal computer (UMPC), a handheld computer, a netbook, a personal digital assistant (PDA), a wearable electronic device, a virtual reality device, etc. Therefore, the embodiments of the present application do not limit the type of electronic device.

[0059] In addition, an embodiment of the present invention also provides a computer-readable medium, on which a computer program is stored. When the computer program is executed by a processor, it realizes any one or more of the prognosis prediction of lung adenocarcinoma patients described in any of the aforementioned embodiments, the prediction of immunotherapy resistance in any of the aforementioned embodiments, and the prediction of the therapeutic effect of targeted drugs in any of the aforementioned embodiments.

[0060] The computer-readable medium may be a general storage medium, such as a mobile disk, a hard disk, and the like.

[0061] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0062] The patient sample information used in the embodiment is as follows:

[0063] This application adheres to the Declaration of Helsinki (revised in 2013). The study design and protocol were approved by the Research Ethics Committee of the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (no. NCC2020C-506, approved on November 17, 2020), and individual informed consent was waived for this retrospective study. Formaldehyde-fixed paraffin-embedded (FFPE) cancer tissue samples and their matched non-tumor tissue samples from 250 patients with LUAD were retrospectively obtained from the biobank of the National Cancer Center (China). The sample size of the study was not further expanded due to cost and some practical issues, but a sample size of more than 200 patients has a 90% power to detect a 10% absolute difference in overall survival associated with IRAK3 levels. Participants were recruited according to the inclusion criteria including primary lung cancer diagnosis between 2006 and 2017, no previous cancer diagnosis, no metastatic disease at diagnosis, stage I / II / III tumors, and surgical resection without preoperative treatment. Patients with stage IV disease who received neoadjuvant therapy and were inoperable were excluded. Patients underwent minimally invasive sublobar resection (109 patients), lobectomy (133 patients), or pneumonectomy (8 patients), as well as lymph node resection or sampling. The original specimens were obtained from the surgery of the enrolled LUAD patients and were fixed in 10% buffered formaldehyde for 24 hours immediately after resection, dehydrated in 70% EtOH, and embedded in paraffin. FFPE sections were cut by a freezing microtome (Leica Microsystems, UK) and stored at room temperature for further analysis. Further adjuvant treatment for patients was carried out according to the guidelines updated in real time. Clinical information on smoking history, age and gender, tumor size, tumor lymph node metastasis stage, and overall survival was retrieved from medical records and follow-up surveys.

[0064] Example 1: Database analysis and data collection

[0065] Experimental methods

[0066] In the Oncomine database (https: / / www.oncomine.org), the mRNA expression level of the IRAK3 gene in different cancer types and their corresponding normal tissues was evaluated. The thresholds were set as follows: genes ranked in the top 10%, P value 0.0001 and fold change 2. The TIMER database (https: / / cistrome.shinyapps.io / timer / ) provides a comprehensive platform for systematic analysis of immune infiltration in various cancer types. Visualization of IRAK3 expression in different types of cancer and their corresponding normal tissues was achieved by the Diff Exp module. In addition, the mRNA expression, DNA methylation data, survival outcomes, and clinical information of all available human cancer types in the TCGA database were obtained from the UCSC Xena website (https: / / xenabrowser.net / datapages / ). The differences in the methylation status of IRAK3 in various cancer types were examined using TCGA data. The methylation status of all CpG sites of IRAK3 was extracted to evaluate the correlation between IRAK3 expression and its methylation level.

[0067] Experimental Results

[0068] Differential expression and methylation of IRAK3 in various human cancer types

[0069] To evaluate the differential expression of IRAK3 between tumors and normal tissues, the transcriptional levels of IRAK3 in different cancer types were comprehensively retrieved through the Oncomine database. The analysis showed that compared with normal tissues, only a few cancer types had increased IRAK3 expression in the dataset, including colorectal cancer, esophageal cancer, kidney cancer, pancreatic cancer, brain and central nervous system tumors, and lymphomas. In contrast, decreased IRAK3 expression can be observed in more cancer types compared with normal tissues, such as lung cancer, breast cancer, bladder cancer, gastric cancer, ovarian cancer, prostate cancer, leukemia, melanoma, and sarcoma ( Figure 1 (A).

[0070] Using TCGA data for complementary evaluation, we extracted RNA-seq data from TCGA and demonstrated the differential expression of IRAK3 in multiple cancer types and their adjacent normal tissues ( Figure 1 Specifically, in the TCGA-LUAD cohort, IRAK3 mRNA expression levels in tumor tissues were found to be lower than those in adjacent normal tissues ( Figure 1 In addition, TCGA methylation data were used to predict whether IRAK3 expression is regulated by methylation in its promoter region. Figure 1Figure D shows the methylation data of the IRAK3 gene in human cancers. Compared with the corresponding normal tissues, the methylation level of IRAK3 is significantly increased in most human cancers. The increased methylation level is contrary to the trend of low mRNA expression in multiple cancer types. IRAK3 expression is significantly negatively correlated with the methylation of the cg20395892 and cg26279550 sites located in the promoter region of the gene (P<0.001, Figure 1 (E, F).

[0071] Example 2: Immunohistochemical staining and scoring

[0072] Experimental methods

[0073] Immunohistochemical staining of paraffin-embedded sections of lung adenocarcinoma tissues and adjacent non-tumor tissues was completed. Briefly, sections were subjected to antigen retrieval in an antigen retrieval buffer at pH 6.0 by microwave treatment. Sections were incubated with anti-IRAK3 (HPA043097, Sigma-Aldrich, Germany) antibody overnight at 4°C and subsequently incubated with secondary antibodies. Two pathologists (WR and ZL) independently scored the slides, considering the staining intensity and the percentage of cells showing positive staining. They were blinded to the patient information and clinical data during the scoring process, and the agreement between the two was more than 90%. Discordant cases were reviewed by an experienced senior pathologist to reach a consensus again. Staining intensity was divided into four grades, namely 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The percentage of staining was evaluated on the following scale: 0 (negative), 1 (<10%), 2 (10-50%), 3 (51-80%), or 4 (>80%). The IHC index is the result of combining the staining intensity and staining ratio scores to determine the expression level. Since there is no clearly recognized cutoff value for IRAK3, we divided the patients into high (IHC index ≥ 6) and low (IHC index < 6) groups according to the median score.

[0074] Experimental Results

[0075] IRAK3 is significantly downregulated in LUAD tissues, and reduced IRAK3 levels are associated with poor prognosis

[0076] In this example, the expression level of IRAK3 in tumor samples and matched non-tumor tissue samples of 250 LUAD patients was detected by immunohistochemical staining, of which 222 patients (89%) generated evaluable test results. Of the remaining 28 samples that could not be included, 16 (57%) were due to insufficient tumor cells, 7 (25%) were due to improper tumor preservation, 4 (14%) were due to insufficient control staining, and 1 (4%) was due to excessive necrosis. We evaluated the positive expression of IRAK3 protein in 222 LUAD samples and found that the level of IRAK3 in tumor tissues was significantly reduced compared with normal tissues ( Figure 2 IHC staining results also showed that IRAK3 expression was mainly localized in the cytoplasm, which was observed in both tumors and normal tissues ( Figure 2 (middle B).

[0077] In addition, this example examined the prognostic potential of IRAK3 in the LUAD cohort and found that IRAK3 levels were significantly correlated with patient survival. According to univariate Cox regression analysis (P = 0.03, Table 1) and Kaplan-Meier analysis (P = 0.03, log-rank test, Figure 2 C), patients with low IRAK3 levels had a poor prognosis. Multivariate Cox proportional hazards regression analysis identified independent prognostic predictors for LUAD patients, including older age (HR = 1.934, P < 0.001), larger tumor size (HR = 1.914, P < 0.001), higher TNM stage (HR = 1.614, P = 0.006), and reduced IRAK3 protein level (HR = 0.710, P = 0.04) (Table 1). Covariates were further examined in the Cox regression model for possible time-varying effects, and no significant deviations from the proportional hazards assumption were found.

[0078] Table 1 Univariate and multivariate analysis of overall survival in LUAD patients

[0079]

[0080]

[0081] Notes: LUAD, lung adenocarcinoma; HR, hazard ratio; CI, confidence interval; TNM stage (tumor-node-metastasis stage).

[0082] We further examined the relationship between IRAK3 expression and lung cancer prognosis in the Kaplan-Meier Plotter database. Figure 2 As shown in Figure D, better lung cancer prognosis (OS HR = 0.76, 95% CI = 0.67 to 0.85, P < 0.001; PFS HR = 0.73, 95% CI = 0.61 to 0.87, P < 0.001) was associated with higher IRAK3 expression. After a more in-depth evaluation of the prognostic potential of IRAK3 in different pathological subtypes of lung cancer, a significant association between IRAK3 expression and patient survival was found only in lung adenocarcinoma ( Figure 2 These results confirm the prognostic value of IRAK3 in lung adenocarcinoma and confirm that decreased IRAK3 levels lead to a poor prognosis.

[0083] Example 3: Survival prognosis analysis

[0084] Experimental methods

[0085] All patients from the National Cancer Center (NCC) LUAD cohort underwent routine examinations every 6 months during the first 5 years of follow-up and annually thereafter. The estimated median follow-up time calculated by the inverse Kaplan-Meier method was 8.0 years. The primary endpoint was the death of the patients. Overall survival (OS) was defined as the time from lung surgery to death from all causes. Progression-free survival (PFS) was defined as the time from surgery to the first progression (including tumor recurrence, contralateral tumor, secondary tumor, or death). Survival analysis was performed using the Kaplan-Meier method using survival data from the NCC LUAD cohort as well as IRAK3 expression levels, and statistical significance was determined using the log-rank test. The Cox proportional hazards model was used to seek to identify independent prognostic factors. The hazard ratio (HR) was calculated as the ratio of the hazard of the high IRAK3 group to the hazard of the low IRAK3 group as a measure to evaluate the impact of IRAK3 on patient survival. Other variables considered in the Cox survival analysis included age, sex, tobacco use, tumor size, histological grade, and TNM stage. At the same time, we plotted the survival curves of overall survival of patients with lung adenocarcinoma with or without lymph node metastasis. The Kaplan-Meier Plotter database (https: / / kmplot.com / analysis / ) includes 2852 NSCLC samples with an average follow-up time of 49.7 months. The relationship between IRAK3 expression and survival of patients with lung cancer, lung squamous cell carcinoma, lung adenocarcinoma, and lung adenocarcinoma with or without lymph node metastasis was thoroughly investigated using Kaplan-Meier Plotter. The corresponding survival curves, including OS and PFS, are graphically represented.

[0086] Experimental Results

[0087] In order to gain a deeper understanding of the mechanism of action of IRAK3 as a prognostic indicator for LUAD, the correlation between IRAK3 levels and clinicopathological characteristics in the lung adenocarcinoma cohort of this application was explored (Table 2).

[0088] Table 2 Correlation study between IRAK3 expression and clinicopathological characteristics of LUAD patients

[0089]

[0090] Note: LUAD, lung adenocarcinoma; TNM stage (TNM stage, tumor-node-metastasis stage); T stage (T stage, tumor stage); N stage (N stage, node stage).

[0091] The results of the chi-square test showed that there was a significant association between IRAK3 levels and histological grade (P = 0.03), TNM stage (P = 0.041), and N stage (P = 0.03). Interestingly, decreased IRAK3 was associated with worse OS in patients with N1 and N2 stages (OS HR = 0.5519, P = 0.02, log-rank test), but was not associated with overall survival in patients with N0 stage (OS HR = 1.035, P = 0.89, log-rank test) ( Figure 3 Here, N stage indicates the involvement of lymph nodes. Specifically, N0 indicates no regional lymph node metastasis, while N1, N2, and N3 indicate lymph node metastasis in different parts.

[0092] In the Kaplan-Meier Plotter database, the correlation between IRAK3 expression and clinical outcomes in patients with lung adenocarcinoma with different clinicopathological factors was further examined. Low expression of IRAK3 was associated with unfavorable OS and PFS in both sexes (P<0.05, Table 3). In addition, IRAK3 expression levels were verified to be significantly correlated with the survival rate of patients with positive lymph nodes in the Kaplan-Meier Plotter database. Specifically, patients with reduced IRAK3 expression in stage N1 patients showed unfavorable outcomes, as shown by Kaplan-Meier analysis (OS HR=0.52, P=0.005, log-rank test, Figure 3 D), while IRAK3 expression level became irrelevant in N0 patients (OS HR=1.22, P=0.16, log-rank test, Figure 3 Middle C). These findings suggest that both the mRNA expression and protein levels of IRAK3 have the potential to affect the prognosis of LUAD patients with lymph node metastasis.

[0093] Table 3 Correlation analysis between IRAK3 mRNA expression and clinical prognosis of LUAD patients with different clinicopathological characteristics in the Kaplan-Meier Plotter database

[0094]

[0095] Example 4: IRAK3 co-expression network and functional enrichment analysis

[0096] Experimental methods

[0097] The LinkedOmics database (https: / / www.linkedomics.org / login.php) contains clinical information and multi-omics data from 10 Clinical Proteomic Tumor Analysis Consortium (CPTAC) cancer cohorts and all 32 TCGA cancer types. LinkedOmics is a unique and accessible platform that enables clinicians and biologists to analyze multi-omics data within and across tumor types. Differentially expressed genes associated with IRAK3 were identified using the LinkFinder module, and enrichment analysis based on Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) functional annotations was performed using the LinkInterpreter module. In addition, the 'clusterProfiler' package was applied to complete gene set enrichment analysis and identify pathways associated with IRAK3-related genes.

[0098] Experimental Results

[0099] Identification of IRAK3 co-expression network and IRAK3-related signaling pathways in LUAD

[0100] In the LinkedOmics web portal, the co-expression network of IRAK3 in TCGA-LUAD was depicted using the LinkFinder module to explore its biological function in lung cancer. Figure 4 As shown in Figure A, there are 6320 genes (highlighted by red dots) that are positively correlated with IRAK3. In contrast, there are 4227 genes (highlighted by green dots) that are negatively correlated with IRAK3. Among them, the top 50 genes positively correlated with IRAK3 and the top 50 negatively correlated genes were generated heat maps ( Figure 4 48 of the top 50 genes positively correlated with IRAK3 showed low HR values, suggesting that they have the potential to be protective markers in LUAD. In contrast, most of the genes negatively correlated with IRAK3 were strongly indicated as high-risk markers with unfavorable HR values ​​( Figure 4 (middle D).

[0101] These results indicate that the IRAK3 co-expression network can affect the outcome and prognosis of LUAD patients.

[0102] To identify the signaling pathways altered by IRAK3, we performed gene set enrichment analysis to detect activated pathways in LUAD. KEGG pathway enrichment analysis showed that genes co-expressed with IRAK3 were mainly involved in B cell receptor signaling pathway, chemokine signaling pathway, leukocyte transendothelial migration, NF-κB signaling pathway, cytokine-cytokine receptor interaction, PD-L1 expression and PD-1 checkpoint pathway in cancer, natural killer cell-mediated cytotoxicity, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, and Th17 cell differentiation ( Figure 4 E). The results of GO term enrichment analysis revealed that the co-expressed genes were mainly enriched in adaptive immune response, plasma membrane outer side, immune effector process, immune receptor activity, activation of immune cell surface receptor signaling pathway, signaling pathway regulating immune response, signal transduction activating immune response, cell surface receptor signaling pathway regulating immune response, leukocyte-mediated immunity, etc. ( Figure 4 Middle F). All GSEA results indicated that IRAK3 and its co-expressed genes have potential roles in triggering and regulating immune responses in LUAD.

[0103] Example 5: IRAK3 and tumor immune microenvironment

[0104] Experimental methods

[0105] The TIMER2.0 (https: / / timer.comp-genomics.org / timer / ) database provides a broad platform for systematic analysis of immune infiltration in various cancer types. Six advanced algorithms, including CIBERSORT, XCELL, EPIC, QUANTISEQ, MCOUNTER, and TIMER, were applied to TCGA data to rigorously evaluate the level of immune cell infiltration within tumors. The relationship between IRAK3 and the infiltration levels of six immune cells was explored by Spearman correlation test. In addition, the exact proportion of different immune cell types in each LUAD sample was calculated using the 'CIBERSORT' package. To assess tumor purity and verify the degree of infiltration of stromal cells and immune cells, the ESTIMATE, immune, and stromal scores of each LUAD sample were quantified using the 'ESTIMATE' R package. The correlation coefficients between IRAK3 and the ESTIMATE score, immune score, and stromal score were calculated by Spearman correlation analysis.

[0106] Experimental Results

[0107] Correlation analysis between IRAK3 and immune infiltration levels in LUAD

[0108] In various cancers, the level of tumor-infiltrating lymphocytes has been suggested to be an independent predictor of sentinel lymph node status and clinical outcomes. Therefore, we examined the potential correlation between IRAK3 and the degree of immune infiltration in LUAD. CIBERSORT analysis was used to examine the differences in immune infiltration between tumors with low and high IRAK3 expression. LUAD patients with high IRAK3 expression showed significantly increased levels of immune cell infiltration compared with patients with low IRAK3 expression ( Figure 5 Spearman correlation was used to evaluate the association between IRAK3 expression and the observed level of immune infiltration. IRAK3 was positively correlated with the abundance of macrophages, CD4+T cells, CD8+T cells, neutrophils, monocytes, etc. (P<0.001, Figure 5 In addition, a series of algorithms including EPIC, MCPCOUNTER, QUANTISEQ, XCELL, and TIMER were used to evaluate the level of immune infiltration in LUAD. At the same time, the results of the TISIDB database showed that IRAK3 was positively correlated with several immune cell types, especially macrophages, monocytes, CD4+T cells, myeloid dendritic cells, and B cells, which was consistent with the results of CIBERSORT analysis ( Figure 6 In addition, the findings of the present application showed that ESTIMATE, immune and matrix scores were significantly increased in LUAD caused by IRAK3 stimulation ( Figure 5 All the above results strongly suggest that IRAK3 is closely associated with immune infiltration in the tumor microenvironment.

[0109] Example 6: Expression of IRAK3 at the single cell level

[0110] Experimental methods

[0111] The Tumor Immunity Single Cell Center 2 (TISCH2) (http: / / tisch.comp-genomics.org / ) is an extensive and instantly updated single-cell RNA sequencing (scRNA-seq) database that supports single-cell transcriptome exploration and interactive visualization of the tumor microenvironment across multiple cancer types. TISCH2 integrates 190 scRNA-seq datasets from tumors, covering more than 6 million cells from different cancer types. At the single-cell level, the expression of IRAK3 in the LUAD_GSE131907 dataset (GEO access number: GSE131907) and LUAD_GSE149655 dataset (GEO access number: GSE149655) was visualized by the dataset module. The heat map of IRAK3 expression in different cell types in all NSCLC datasets was obtained by the gene module. In addition, correlation analysis was used to calculate the correlation coefficient between IRAK3 and myeloid cell lineage-specific genes, including CD45, CD11b, and CD11c.

[0112] Experimental Results

[0113] Specific expression of IRAK3 in monocytes / macrophages

[0114] To investigate how IRAK3 affects the tumor immune microenvironment, publicly available single-cell RNA-seq (scRNA) data were extracted to examine the expression levels of IRAK3 in various immune and stromal cells in the LUAD microenvironment. IRAK3 was found to be mainly expressed in monocytes / macrophages, endothelial cells, and fibroblasts ( Figure 7 In addition, IRAK3 expression was positively correlated with immune cell markers including CD45 (R = 0.442, P < 0.001), CD11b (R = 0.362, P < 0.001), and CD11c (R = 0.402, P < 0.001) in the selected LUAD dataset ( Figure 7 Middle D). The strong correlation observed suggests that IRAK3 is primarily expressed by myeloid cells, including monocytes and macrophages.

[0115] Example 7: IRAK3 and immunotherapy response

[0116] Experimental methods

[0117] The Tumor Immune Dysfunction and Exclusion (TIDE) database (http: / / tide.dfci.harvard.edu / ) is an interactive and comprehensive resource library. The computational methods behind it are designed to predict immunotherapy response based on gene expression profiles and evaluate the immune escape potential of different tumors. The TCGA-LUAD cohort was used to examine the impact of IRAK3 on immunotherapy response in tumor cases. The TIDE score, T cell dysfunction score, and exclusion score were obtained for each patient using the TIDE algorithm. Among them, the TIDE score was used to predict immunotherapy response and evaluate tumor immune escape. The T cell dysfunction score was used to examine the correlation between CTLs levels and overall survival of patients under different IRAK3 levels. In contrast to dysfunction, the T cell exclusion score is derived from a gene signature associated with immunosuppressive cells and predicts immune escape. In addition, microsatellite instability (MSI) and tumor mutation burden (TMB) are considered as indicators to predict the efficacy of immunotherapy in various cancers. Simple nucleotide variation data were obtained from the TCGA-LUAD cohort to calculate the tumor mutation burden. The MSI of the TCGA-LUAD cohort was also extracted from the TIDE database. Spearman correlation analysis was used to evaluate the relationship between IRAK3 and immune checkpoint markers including BTLA, PDCD1, PDCD1LG2, CD274, HAVCR2, CTLA4, TIGIT, and LAG3.

[0118] Experimental Results

[0119] Correlation between IRAK3 expression and immunotherapy response

[0120] Cancer immunotherapy using immune checkpoint blockers (ICBs) can activate the immune system to recognize and eradicate tumor cells, but ICBs are only effective in about one-third of patients in various cancer types. Identifying sensitive and reliable ICB response biomarkers is critical for tumor patients. This example uses the TIDE algorithm to calculate the expected response of TCGA-LUAD patients to immunotherapy. The findings of this application show that IRAK3 expression is significantly reduced in LUAD patients who show higher responsiveness to immunotherapy compared to patients who show resistance to immunotherapy, ( Figure 8 (A). TIDE scores were also significantly increased in the high IRAK3 group. This suggests that LUAD patients with high IRAK3 levels are more likely to be unresponsive to ICB therapy compared with patients with low IRAK3 expression (P < 0.001, Figure 8 In addition, elevated MSI and TMB levels were observed in the low IRAK3 group (P < 0.001 and P < 0.001, respectively). Figure 8B, C), while the high IRAK3 group showed higher T cell dysfunction scores (P<0.001, Figure 8 Middle C). These findings suggest that IRAK3 expression is associated with tumor immune escape and immunotherapy resistance. In the future, IRAK3-targeted drugs may reduce T cell dysfunction and increase MSI and TMB, thereby improving ICB response rates.

[0121] This example delves into how IRAK3 promotes resistance to immunotherapy. Using the TIDE database, it was found that cytotoxic T lymphocytes are major players in the anti-tumor immune response, and when they are in a dysfunctional state, the ability to control tumor growth may be impaired. In the TCGA LUAD cohort, enhanced CTL levels were associated with improved patient survival, especially when IRAK3 expression was low. However, elevated IRAK3 expression weakened or even reversed the positive effects of CTL ( Figure 8 These results suggest that IRAK3 promotes resistance to immunotherapy by exacerbating the dysfunction of cytotoxic T lymphocytes through multiple pathways. Gene co-expression analysis showed that IRAK3 was positively correlated with the expression of immune checkpoint markers, including PDCD1 (PD-1), CD274 (PD-L1), CTLA4, LAG3, and TIGIT ( Figure 8 All immune checkpoint markers were significantly elevated in patients with high IRAK3, suggesting a link between IRAK3 expression and immune escape and immunotherapy response ( Figure 8 In addition, the signature gene set enrichment analysis showed that IRAK3 significantly activated the inflammatory response, interferon-γ response and IL-6 / JAK / STAT3 signaling pathway ( Figure 8 Middle G, Fig. 9 In addition, this example verifies the correlation between IRAK3 and key components of the above pathways that contribute to resistance to immunotherapy ( Fig. 9 (middle D).

[0122] Example 8: IRAK3 and drug reaction

[0123] Experimental methods

[0124] The Genomics of Drug Sensitivity in Cancer (GDSC) database (https: / / www.cancerrxgene.org / ) is a comprehensive and easily accessible resource that provides potential drug response biomarkers and detailed information on the sensitivity of tumor cells to multiple drugs. The GDSC1 and GDSC2 datasets were used to assess the response of each patient to various chemotherapy and molecular targeted drugs. The IC 50 The value is the half inhibitory concentration.

[0125] Experimental Results

[0126] The half-maximal inhibitory concentration (IC ) of various molecular targeted and chemotherapeutic drugs commonly used in LUAD treatment was calculated by the 'oncoPredict' software package. 50 ) value. The calculated value was intended to predict the treatment response of patients with different IRAK3 expression levels. It was found that IRAK3 was significantly negatively correlated with the half-maximal inhibitory concentration of Dabrafenib (R = -0.34, P < 0.001), Crizotinib (R = -0.33, P < 0.001), Epirubicin (R = -0.32, P < 0.001), Oxaliplatin (R = -0.31, P < 0.001), AZD8055 (R = -0.30, P < 0.001) and Taselisib (R = -0.30, P < 0.001) ( Fig.10 Middle A). The high IRAK3 group showed significantly lower IC of anti-tumor drugs 50 values, indicating a better response to treatment ( Fig.10 Middle B). These findings provide valuable insights into tailoring therapeutic strategies based on IRAK3 expression levels.

[0127] Example 9: Clinical cohort validation of IRAK3 in predicting the efficacy of immunotherapy

[0128] Experimental methods

[0129] To verify the efficacy of IRAK3 in predicting the efficacy of immunotherapy, 84 patients with lung adenocarcinoma who received immunotherapy with immune checkpoint inhibitors were enrolled. Tumor tissues were obtained from all patients after neoadjuvant immunotherapy. RNA was extracted from the samples immediately and reverse transcription quantitative PCR was performed to determine the expression level of IRAK3 gene mRNA. The IRAK3 gene primers used were: (forward) 5'-CAGCTGGCTGGATGTTCGT-3'; (reverse) 5'-TGTGCCCAGGACCAAAGTAA-3'. The efficacy of immunotherapy in the above patients was determined by oncologists and surgeons after the course of treatment.

[0130] Experimental Results

[0131] In a validation cohort of 84 LUAD patients, IRAK3 gene expression was found to be an excellent marker for predicting the efficacy of immunotherapy. RT-qPCR results showed that IRAK3 expression in the immune response group of 84 tumor samples was much lower than that in the non-response group ( Fig.11 The receiver operating characteristic (ROC) curve of IRAK3 expression predicting immune efficacy showed that the area under the curve (AUC) of IRAK3 as a marker was as high as 0.891 ( Fig.11 (B, P < 0.0001). Further, when different cutoff values ​​were used, the sensitivity and specificity of IRAK3 expression as a predictor of immunotherapy efficacy were shown in Figure 2. Fig.11 As shown in C, the optimal cutoff value is 0.4171, which corresponds to a specificity of 88.10% and a sensitivity of 85.71%.

[0132] The above examples were statistically evaluated using SPSS statistical software 22 (SPSS, Chicago, IL, USA), GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA) or R software (version 4.3.1). The relationship between clinical pathological characteristics and IRAK3 expression was evaluated by chi-square test. Patient survival was analyzed using the Kaplan-Meier method, and statistical significance was evaluated using the log-rank test. In addition, in order to determine independent prognostic factors, survival data were fitted using the Cox proportional hazard model. Correlation analysis used the Pearson and Spearman method. The statistical significance test between different groups was completed by a two-tailed Student's t test, and the results were reported as mean ± standard deviation (SD). It was defined as statistically significant when P<0.05.

[0133] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of a reagent for detecting IRAK3 expression level in the preparation of a product for predicting the prognosis of patients with lung adenocarcinoma.

2. The use according to claim 1, It is characterized in that The lung adenocarcinoma patients include lung adenocarcinoma patients with lymph node metastasis.

3. The use according to claim 1 or 2, It is characterized in that The IRAK3 expression level includes at least one of an IRAK3 protein expression level and an IRAK3 mRNA expression level.

4. Use of a reagent for detecting IRAK3 expression level in the preparation of a product for predicting resistance to immunotherapy and / or predicting the therapeutic effect of a targeted drug.

5. The use according to claim 4, It is characterized in that The immunotherapy includes immune checkpoint inhibitor therapy.

6. The use according to claim 4, It is characterized in that The targeted drug includes at least one of dapafenib, crizotinib, epirubicin, oxaliplatin, AZD8055 and Taselisib.

7. A method for training a prediction model, wherein the prediction model is applied to any one or more of the following: prognosis prediction, immunotherapy resistance prediction, and treatment effect prediction of targeted drugs in patients with lung adenocarcinoma. It is characterized in that It includes: Obtain the detection results of the IRAK3 expression level of the training samples and their corresponding annotation results; Input the obtained detection results and annotation results into the pre-built machine learning model to obtain the prediction results of the samples; According to the labeling results and prediction results, the parameters of the machine learning model are updated.

8. A prediction device, the prediction device being applied to any one or more of the following: prediction of prognosis of patients with lung adenocarcinoma, prediction of resistance to immunotherapy, and prediction of therapeutic effect of targeted drugs. It is characterized in that It includes: An acquisition module is used to obtain the detection result of the expression level of IRAK3 of the sample to be tested; The prediction module is used to input the obtained detection results into the prediction model trained by the training method described in claim 7 to obtain the prediction results of the samples.

9. An electronic device, It is characterized in that It includes a processor and a memory, wherein the memory is used to store a program, and when the program is executed by the processor, the processor realizes any one or more of the following: prognosis prediction of lung adenocarcinoma patients, immunotherapy resistance prediction, and treatment effect prediction of targeted drugs; The step of predicting the prognosis of patients with lung adenocarcinoma comprises: obtaining the test result of the expression level of IRAK3 of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method of claim 7 to obtain the prediction result of the prognosis of the sample; The step of predicting immunotherapy resistance comprises: obtaining the test result of the expression level of IRAK3 of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method of claim 7 to obtain the prediction result of the immunotherapy resistance of the sample; The step of predicting the therapeutic effect of the targeted drug includes: obtaining the test result of the IRAK3 expression level of the sample to be tested; inputting the obtained test result into the prediction model trained by the training method of claim 7 to obtain the prediction result of the therapeutic effect of the targeted drug of the sample.

10. A computer readable medium, It is characterized in that The computer-readable medium stores a computer program, which, when executed by a processor, implements any one or more of the prognosis prediction of lung adenocarcinoma patients as claimed in claim 9, the prediction of immunotherapy resistance as claimed in claim 9, and the prediction of the therapeutic effect of targeted drugs as claimed in claim 9.